# Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

> **NCT00532883** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 44 (actual)

## Conditions studied

- Hemoglobin SC Disease

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** Magnesium Pidolate
- **OTHER:** Placebo Pills and Placebo Liquid

## Key facts

- **NCT ID:** NCT00532883
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-08
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Enrollment has been terminated due to a slow rate of enrollment.
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532883, "Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00532883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*